Kogenate® FS - antihemophilic factor (recombinant) for the Treatment of Hemophilia A

Important Information for the Hemophilia Community Regarding Triad Group’s Alcohol Prep Products and Bayer’s BayCuff™ and First Aid Kit… learn more »

Important Safety Information
Prescribing Information »

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF. Continue Reading Below »

Patients Parents and Caregivers Healthcare Providers

Kogenate^® FS is a recombinant factor VIII product indicated for the treatment of hemophilia A.

As the maker of Kogenate FS, Bayer is proud of its commitment to the hemophilia A community.

* The starting date of room temperature storage should be clearly recorded on the unopened product carton. Once stored at room temperature, the product must not be returned to the refrigerator. The shelf-life then expires after the storage at room temperature (up to 12 months), or the expiration date on the product vial, whichever is earlier.
** Up to 6 free samples/doses to a maximum of 5,000 IU for new patients and 20,000 IU for previously treated patients.

INDICATIONS & USAGE

Kogenate® FS, antihemophilic factor (recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Kogenate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

IMPORTANT SAFETY INFORMATION

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Kogenate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For important risk and use information, please see the full prescribing information.

Prescribing Information | Privacy Policy | Terms of Use | Sitemap

Kogenate FS Antihemophilic Factor (Recombinant) with BIO-SET Needleless Reconstitution System